30-Day Unplanned Readmit Rate Low but Costly in Head, Neck Sx

This article originally appeared here.
Share this content:
30-Day Unplanned Readmit Rate Low but Costly in Head, Neck Sx
30-Day Unplanned Readmit Rate Low but Costly in Head, Neck Sx

WEDNESDAY, April 22, 2015 (HealthDay News) -- For patients undergoing head and neck surgery, 30-day unplanned readmission rates are low, but costly, according to a review published online March 9 in Head & Neck.

Peter T. Dziegielewski, M.D., from The Ohio State University Wexner Medical Center in Columbus, and colleagues conducted a retrospective review involving 607 patients undergoing 660 head and neck operations. The authors sought to determine the rate, predictors of, and costs of 30-day unplanned readmissions. Risk factors for 30-day unplanned readmissions were identified in logistic regression analyses.

The researchers found that 7.3 percent of cases had 30-day unplanned readmission. Coronary artery disease (odds ratio [OR], 2.8), chronic renal failure (OR, 3.56), not attending preoperative clinic (OR, 2.74), length of stay greater than five days (OR, 3.19), and presence of a gastrostomy tube (OR, 2.75) were identified as significant independent risk factors for readmissions. The total cost of 30-day unplanned readmissions was $1.68 million.

"Thirty-day unplanned readmissions in head and neck surgery patients can be low, but costly," the authors write. "Identifying patients at risk for 30-day unplanned readmissions will help develop preventative strategies."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »